Published in Scientific Reports: Researchers from the US and Flinders University have developed a potent vaccine formulation against the triggers of Alzheimer's disease.
The US-led study used an adjuvant technology developed by Australian biotech Vaxine Pty Ltd to deliver a combination of vaccines against aberrant forms of the anti-amyloid-beta and anti-tau proteins.
The formation of plaques by amyloid-beta is believed to drive Alzheimer’s disease, while the accumulation of pathological tau also correlates with dementia in Alzheimer’s patients.The vaccines against these hallmark proteins of Alzheimer's were produced through a universal vaccine platform, called MultiTEP, which the US researchers developed with funding from the National Institute of Health (NIH) and the Alzheimer's Association.
According to the researchers, the MultiTEP platform-based vaccines generate strongly binding antibodies against the disease targets but do not induce potentially harmful auto-reactive cellular immune responses.
The results presented in Scientific Reports suggests that a combination of anti-amyloid-beta and ant-tau proteins delivered with the Vaxine Advax™ adjuvant technology could lead to both preventative and therapeutic approaches in Alzheimer's.
The next step of the research collaboration are non-clinical safety-toxicology studies to fulfil US Government safety standards for the Investigational New Drug application. If successful, the immunogenicity and efficacy will then be subject of human trials.